Close menu




MORPHOSYS AG O.N.

Photo credits: pixabay.com

Commented by André Will-Laudien on January 30th, 2023 | 09:13 CET

Mega biotech rally 2023! Defence Therapeutics, Bayer, BioNTech, Morphosys - Where to put the money?

  • Biotechnology
  • Cancer
  • Covid19
  • Investments

Who would have thought it? Since the beginning of the year, the stock markets have been jubilant despite difficult predictions about the economic trend in 2023. High inflation and rising interest rates are not a good breeding ground for the popular biotech stocks because they have to constantly refinance their research expenses. As the risk fee is readjusted as costs rise, investors demand higher premiums for providing money. However, some biotech stocks have taken off since the beginning of the year despite adverse conditions. What is their secret?

Read

Commented by André Will-Laudien on January 5th, 2023 | 06:35 CET

It is the year 2023 and COVID is back! BioNTech, Bayer, Defence Therapeutics, Morphosys - Which stocks stand up to the virus from China?

  • Biotechnology
  • Covid19
  • Cancer

The next COVID wave is raging in China. The situation is no less dramatic today than in 2019 because until now, only vaccines produced in the country may be administered to locals in China. Before Christmas, however, the German government obtained permission to have Germans in China vaccinated with the active ingredient from BioNTech and immediately had the first doses flown out to Beijing. Yesterday, the EU discussed a joint reaction to the current conditions in China. German medical officials are calling for mandatory Europe-wide testing of all people entering the country and are warning of a new, dangerous virus mutation due to the large numbers of infections. Investors are therefore taking the vaccine experts back into focus.

Read

Commented by Juliane Zielonka on December 23rd, 2022 | 08:00 CET

BioNxt Solutions, MorphoSys, BioNTech - Innovations and scaling potential for the portfolio

  • Biotechnology

Around the world, patients are used to swallowing medicines in pill form. Sales of oral, fixed-dose drugs alone accounted for a whopping 23.8% of the global pharmaceutical drug delivery market in 2021. That is reason enough for Canadian biotech company BioNxt Solutions to further expand its strategic pole position. BioNxt Solutions secures further rights to a unique platform technology in this segment. Caution is currently the order of the day for MorphoSys. Analysts downgrade the target price from EUR 16 to EUR 12 after a disappointing Q3. BioNTech, on the other hand, can expand its dominance. The Mainz-based company is scaling up in the Asia-Pacific region with new production sites.

Read

Commented by Fabian Lorenz on December 19th, 2022 | 13:57 CET

BioNTech top, Morphosys flop and Defence Therapeutics takeover candidate?

  • Biotechnology
  • vaccine
  • Cancer

Biotech shares are volatile. Investors were reminded of this again just last week. Moderna shares initially rose by almost 30%, only to fall back by around 10% towards the weekend. But overall, the mood in the biotech segment was positive. Moderna reported positive study results on a combination therapy of a Moderna cancer vaccine and the tumor drug pembrolizumab from Merck & Co. At BioNTech, two buy recommendations and the expansion in Asia created a good mood. This mood has also prevailed at Defence Therapeutics for several weeks. The Canadians reported positive study results against tumors, and their Accum technology delivers what it promises, in which case mRNA specialists such as Moderna, BioNTech and Co. should be interested in a cooperation or even acquisition. In contrast, Morphosys slides to a new multi-year low.

Read

Commented by André Will-Laudien on December 5th, 2022 | 12:43 CET

Attention biotech stocks: Bayer, BioNTech, Defence Therapeutics and Morphosys - These stocks look good!

  • Biotechnology
  • Cancer
  • research

After months of selling off, they are back: biotech stocks! A strong turn on the NASDAQ quickly flushed the beaten-up stocks back to the top of the hit lists. With COVID out of the spotlight, companies are returning to their long-term research lines. These have been heavily focused on cancer in recent years, and now there is even groundbreaking news on metastasis. BioNTech has thus already gained more than 40% since the October low. Morphosys, on the other hand, lost another 40% after an Alzheimer's study failed to deliver valuable results. It is worth taking another look at the sector.

Read

Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

  • Biotechnology
  • Cancer
  • Investments

Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

Read

Commented by Stefan Feulner on November 21st, 2022 | 11:07 CET

Morphosys, Defence Therapeutics, Evotec - Stabilization after the sell-off

  • Biotechnology
  • Investments

After the publication of the figures for the third quarter, many biotech companies were able to surprise positively. Due to the partly panic-like sell-off in this capital-intensive sector, there are attractive entry opportunities at a strongly discounted level, which should pay off with disproportionate price gains in the long term. The fact that promising companies are already trading below their cash levels shows that the panic is exaggerated. There are currently signs of a bottoming out, which could herald the next upward wave.

Read

Commented by Juliane Zielonka on November 18th, 2022 | 11:25 CET

Pfizer, Cardiol Therapeutics, Morphosys - Heart disease and cancer are on the rise!

  • Biotechnology
  • Cancer
  • heartdisease

No sooner is the Coronavirus in retreat than the damage caused by the pandemic measures comes to light. Young men, in particular, are affected by heart inflammation after two vaccinations with the Pfizer or Moderna vaccine. Reason enough for both companies to react to the research results of a small Canadian study with a new study that brought exactly that to light. On the other hand, the increase in myocarditis and pericarditis represents a great opportunity for Cardiol Therapeutics to successfully develop its active ingredient against pericarditis. So far, there is only one treatment available in the US that is purely inpatient, and it is in the five-digit USD range. With Cardiol's active ingredient, it may be possible to contain pericarditis more economically and effectively. Another consequence of the pandemic is an increase in cancer cases. Due to late diagnosis and a lack of access to health care, cancer is becoming a global health problem. Morphosys, still reeling this week from disappointing Alzheimer's trial results, however, has promising drugs in the pipeline.

Read

Commented by André Will-Laudien on November 16th, 2022 | 11:27 CET

That hit home! Roche and Morphosys fail with Alzheimer's study, Bayer and Defence Therapeutics continue to rise strongly

  • Biotechnology
  • Cancer

It is common for biotech stocks to publish study results as well as figures several times a year. Since there are usually only expenses and few sales to report for these stocks fundamentally, analysts focus on the clinical successes in the way of a trial for the approval of new active substances. This can sometimes lead to erratic price movements. Roche and Morphosys suffered the same fate at the beginning of the week, with their share prices plummeting on the back of bad news. We take a look at a hot sector.

Read

Commented by Nico Popp on November 15th, 2022 | 13:30 CET

This hydrogen news moves the share prices today: dynaCERT, Morphosys, Varta

  • hydrogen
  • Automotive

When news moves prices, chart analyses and analysts' assessments are invalidated in one fell swoop. Today, momentum is building for the hydrogen stock dynaCERT. The reason: The Company, together with its new distribution partner, has announced deliveries to renowned mining groups. Among them are Vale, Nexa Resources and Antamina, one of the ten largest mining companies in the world. Is this a breakthrough for HydraGEN™ technology? We shed light on the exciting situation surrounding dynaCERT and also use the examples of MorphoSys and Varta to explain how investors can react when everything suddenly changes.

Read